Madrigal Pharmaceuticals Inc YDO1
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if YDO1 is a good fit for your portfolio.
News
-
Madrigal's stock surges as FDA approves first drug for liver disease MASH
-
Madrigal Shares Leap Premarket on First FDA NASH Green Light
-
Madrigal Pharmaceuticals Wins Accelerated Approval for Rezdiffra From FDA
-
Madrigal Gets FDA Priority Review of Resmetirom in NASH With Liver Fibrosis
-
Tesla and Canopy Growth stocks surge, RTX and J.M. Smucker shares fall, and other stocks on the move
-
Madrigal Pharmaceuticals shares fall after new CEO named
-
Madrigal Pharmaceuticals' stock up 5% as company starts rolling submission for FDA approval of NASH treatment
-
Weight-loss drugs in development aim to replace injections with pills
Trading Information
- Previous Close Price
- $261.70
- Day Range
- $257.10–257.10
- 52-Week Range
- —–293.00
- Bid/Ask
- $258.00 / $260.70
- Market Cap
- $5.48 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 376
- Website
- http://www.madrigalpharma.com
Comparables
Valuation
|
Metric
|
YDO1
|
CBAY
|
MORF
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.75 | 12.65 | 2.00 |
Price/Sales | — | 111.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
YDO1
CBAY
MORF
Financial Strength
|
Metric
|
YDO1
|
CBAY
|
MORF
|
|---|---|---|---|
Quick Ratio | 9.26 | 10.70 | 37.20 |
Current Ratio | 9.39 | 10.96 | 38.17 |
Interest Coverage | −31.95 | −5.27 | — |
Quick Ratio
YDO1
CBAY
MORF
Profitability
|
Metric
|
YDO1
|
CBAY
|
MORF
|
|---|---|---|---|
Return on Assets (Normalized) | −74.33% | −30.06% | −18.85% |
Return on Equity (Normalized) | −125.94% | −51.97% | −19.43% |
Return on Invested Capital (Normalized) | −95.71% | −30.87% | −23.26% |
Return on Assets
YDO1
CBAY
MORF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Lfknrjwth | Qkjtpjy | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hncpmcgvl | Hjlhfxs | $114.2 Bil | |||
| Moderna Inc
MRNA
| Ydvtxxw | Tkzv | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Zhggdqv | Pdjq | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Vyfspcfp | Tldt | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qptzxst | Dxnng | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dyjptklql | Fwqfzlh | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Pgwjmqbqx | Hglm | $12.8 Bil | |||
| Incyte Corp
INCY
| Wdqcgxdlp | Jrwjcs | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Fdjrhtlwz | Fgntrl | $12.2 Bil |